Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

http://www.wikidata.org/entity/Q42930469

about

Behavior of antibiotics during human necrotizing pancreatitis.The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.Antimicrobial activity of human pancreatic juice and its interaction with antibiotics.Imipenem concentrations in colorectal surgery and impact on the colonic microflora.Pharmacokinetics of FCE 22891, a new oral penem.Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans.Using imipenem and cilastatin during continuous renal replacement therapy.Human variability in susceptibility to toxic chemicals--a preliminary analysis of pharmacokinetic data from normal volunteers.In vitro and pharmacokinetic properties of the carbapenems.Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice Radiolabeled quaternary carbapenems and their interactions with human serum albumin.Cilastatin does not alter superoxide dismutase activity.Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography.Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.Multiple-dose pharmacokinetics of imipenem-cilastatin.Pharmacokinetics of imipenem-cilastatin in neonates.Single-dose pharmacokinetics of imipenem-cilastatin in neonates.Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis Degradation kinetics of imipenem in normal saline and in human serum.Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.Hydrophilic interaction chromatography/tandem mass spectrometry for the simultaneous determination of three polar non-structurally related compounds, imipenem, cilastatin and an investigational beta-lactamase inhibitor, MK-4698, in biological matric Imipenem/cilastatin.

P2860

Q33753205-68845C53-7C53-4B96-B26A-20B0BFF9B919 Q34621525-CD98B2E4-DE61-4895-9F57-EF3F311F6807 Q35126768-FCF646AD-A303-4A20-93FB-7ACCDB4B32A6 Q35244314-A6CE5780-8B94-40DC-A627-F50E77DB47A8 Q35258286-299C32B9-3FB6-4E90-8D1D-43DB818FC3B5 Q35807561-995BFD97-4410-4231-90AB-1735D758A8FF Q36338191-447D0CBE-94E6-40DC-851D-9A2E10929C84 Q36457487-3AAE233F-31DA-41A6-9890-229BCDB4AA2D Q39747565-2F28A131-7BFA-439E-AEA0-1880710634A6 Q39817374-24EC10BC-C526-4ADF-9090-38390AB58282 Q39817622-21ACDC8F-21A0-4966-8A2E-985E7594393F Q39834286-25238A5E-FBDF-4FE3-96ED-04F67E7ABF4D Q39848938-C9E90204-C549-4955-AAF8-B25E066032F7 Q39849271-B63F69F8-1B43-4E29-A019-16C6E712EF82 Q39849277-0D457F14-7A20-44AC-ADBE-D84AF144F8B1 Q39849539-0FA80BD0-2402-472C-812F-91B0FEC3FC65 Q39849620-13E31F91-3AB1-4B67-8561-C5E143167CAF Q39849680-2B3ECAF7-0A75-4A2F-AD08-E750C63FA2D0 Q40283679-4C26BF84-E590-4E20-9F22-8482412877C0 Q42180547-CFC570D9-1611-4B59-9DF3-37005F0CCA03 Q42186280-16F4D4FD-CC41-4CF3-B925-B335B3D024BB Q44419033-B49C7E54-324B-40A1-92E6-00CED576F55C Q45967729-BBA2FDB4-4A3A-421A-BD1B-8C5883620EAB Q54467055-CA38F08F-B4DA-4B03-A12C-0452D7A045B0

P2860

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

http://www.wikidata.org/entity/Q42930469

description

1983 nî lūn-bûn

@nan

1983年の論文

@ja

1983年論文

@yue

1983年論文

@zh-hant

1983年論文

@zh-hk

1983年論文

@zh-mo

1983年論文

@zh-tw

1983年论文

@wuu

1983年论文

@zh

1983年论文

@zh-cn

name

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

@en

Pharmacokinetics and tolerance of N-formimidoyl thienamycin

@nl

type

label

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

@en

Pharmacokinetics and tolerance of N-formimidoyl thienamycin

@nl

prefLabel

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

@en

Pharmacokinetics and tolerance of N-formimidoyl thienamycin

@nl

P1433

Q42930469-06E3C7AF-D62E-4E66-BE95-5F68B322188C

P1476

Q42930469-BB4CDBEE-AA74-4CEB-835E-DA6443FEA54D

P2093

Q42930469-1BA6BBD1-FEB0-465E-919F-0873ED62B79F

Q42930469-1C6DA98B-715F-4ED3-BA1E-81BA0D351B4A

Q42930469-3ADD1F4C-858B-4410-90E0-2F6A3DCD5DEE

Q42930469-67D99EF3-F165-4B49-961E-28E6D1D4FB0B

Q42930469-8C1BDA6A-D02A-443A-A4F9-2492045FD4BF

Q42930469-C371ACA4-3105-4307-853C-343CA17013E2

Q42930469-D6E65490-B334-446D-AD74-466B6A0ECA7E

Q42930469-E9F3908E-710C-4D67-B2DC-A2C5C82A95AA

P2860

Q42930469-293C5C5A-4297-4730-923A-C3FEF695520E

Q42930469-4AE315CA-2B46-4533-9A27-6F46A42BD8B5

Q42930469-4C99D73E-0B33-4297-9961-3E1F872F7298

Q42930469-A4A36E1C-0881-48D8-9C32-B83F21522A4F

Q42930469-D0A5B59C-A4E5-440E-BB96-470C729DB177

Q42930469-DA582F68-1618-44C6-85EA-20560EDBF24D

Q42930469-DE606938-9482-4C4E-94B1-801802C9C408

Q42930469-F5EFE3CB-E1E0-48F9-BA2F-C966468290DF

Q42930469-FA7EAE35-98C3-46DA-ACBD-60EE55F7B20E

Q42930469-FBF0373A-888B-4CBA-8C5F-CEEB1C0F5105

P304

Q42930469-5A44AF9D-60D6-488C-8173-C48A13AADB52

P31

Q42930469-C4883533-7C0D-497E-AE69-19A1A971685E

P356

Q42930469-5A4887B0-8E9E-4C36-8976-485CD2B7DF62

P407

Q42930469-25537F95-45C5-48BF-87E4-554F9EC4FECE

P433

Q42930469-8325CD07-99EE-4B35-902A-4A2292199444

P478

Q42930469-EC652E2D-A88E-4EDA-8848-033501B49096

P577

Q42930469-D4E09ED9-92DB-4A2B-B42B-94353B707D6E

P698

Q42930469-1EDA1100-805B-47B2-99DE-4CB670424D68

P932

Q42930469-F51F78E3-E53A-4CC0-8E1E-3A9FDAA39993

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

@en

P2093

Alestig K

http://www.w3.org/2001/XMLSchema#string

Ferber F

http://www.w3.org/2001/XMLSchema#string

Huber JL

http://www.w3.org/2001/XMLSchema#string

Jones KH

http://www.w3.org/2001/XMLSchema#string

Kahan FM

http://www.w3.org/2001/XMLSchema#string

Meisinger MA

http://www.w3.org/2001/XMLSchema#string

Norrby SR

http://www.w3.org/2001/XMLSchema#string

Rogers JD

http://www.w3.org/2001/XMLSchema#string

P2860

Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics

The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds

MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase

In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp

In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.

In vitro activity of N-formimidoyl thienamycin (MK0787).

Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Kinetic parameter estimation by numerical algorithms and multiple linear regression: theoretical.

P304

293-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.23.2.293

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

1983-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6573156

http://www.w3.org/2001/XMLSchema#string

P932

186040

http://www.w3.org/2001/XMLSchema#string